Inhibition of SARS-CoV-2 infection in human cardiomyocytes by targeting the Sigma-1 receptor disrupts cytoskeleton architecture and contractility
Salerno, J. A.; Torquato, T.; Temerozo, J. R.; Goto-Silva, L.; Mendes, M. A.; Sacramento, C. Q.; Fintelman-Rodrigues, N.; Vitoria, G.; Souza, L. R. Q.; Ornelas, I. M.; Verissimo, C.; Karmirian, K.; Pedrosa, C. d. S. G.; Dias, S. d. S. G.; Soares, V. C.; Aragao, L. G. H. S.; Puig-Pijuan, T.; Salazar, V. W.; Dariolli, R.; Biagi, D.; Furtado, D. R.; Borges, H. L.; Bozza, P. T.; Guimaraes, M. Z. P.; Souza, T. M. L.; Rehen, S.
10.1101/2021.02.20.432092 bioRxivShow abstract
Heart dysfunction, represented by conditions such as myocarditis and arrhythmia, has been reported in COVID-19 patients. Therapeutic strategies focused on the cardiovascular system, however, remain scarce. The Sigma-1 receptor (S1R) has been recently proposed as a therapeutic target because its inhibition reduces SARS-CoV-2 replication. To investigate the role of S1R in SARS-CoV-2 infection in the heart, we used human cardiomyocytes derived from induced pluripotent stem cells (hiPSC-CM) as an experimental model. Here we show that the S1R antagonist NE-100 decreases SARS-CoV-2 infection and viral replication in hiPSC-CMs. Also, NE-100 reduces cytokine release and cell death associated with infection. Because S1R is involved in cardiac physiology, we investigated the effects of NE-100 in cardiomyocyte morphology and function. We show that NE-100 compromises cytoskeleton integrity and reduces beating frequency, causing contractile impairment. These results show that targeting S1R to challenge SARS-CoV-2 infection may be a useful therapeutic strategy but its detrimental effects in vivo on cardiac function should not be ignored.
Matching journals
The top 10 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- A roadmap for the characterization of energy metabolism in human cardiomyocytes derived from induced pluripotent stem cells 95%
- Loss of Acta2 in cardiac fibroblasts does not prevent myofibroblast differentiation or affect cardiac repair after myocardial infarction 94%
- Misoprostol Attenuates Cardiomyocyte Proliferation in the Neonatal Heart Through Bnip3 and Perinuclear Calcium Signaling 94%
Similar papers in this journal
- Cryopreservation of human pluripotent stem cell-derived cardiomyocytes is not detrimental to their molecular and functional properties 96%
- Blebbistatin protects iPSC-CMs from hypercontraction and facilitates automated patch-clamp based electrophysiological study 94%
- Non-permissive SARS-CoV-2 infection in human neurospheres 92%
Similar papers in this journal
- Effects of Emodin, a Plant-Derived Anthraquinone, on TGFβ1-Induced Cardiac Fibroblast Activation and Function 94%
- Copper impedes calcification of human aortic vascular smooth muscle cells through inhibition of osteogenic transdifferentiation and promotion of extracellular matrix stability 90%
- SLO2.1/NALCN Functional Complex Activity in Mouse Myometrial Smooth Muscle Cells During Pregnancy. 90%
Similar papers in this journal
- AARS2 ameliorates myocardial ischemia via fine-tuning PKM2-mediated metabolism 95%
- Human Erbb2-induced Erk Activity Robustly Stimulates Cycling and Functional Remodeling of Rat and Human Cardiomyocytes 94%
- Mettl3-mediated m6A modification of Fgf16 restricts cardiomyocyte proliferation during heart regeneration 94%
Similar papers in this journal
- Impact of neurons on patient derived-cardiomyocytes using organ-on-a-chip and iPSC biotechnologies 92%
- Multi-modal analysis of satellite cells reveals early impairments at pre-contractile stages of myogenesis in Duchenne muscular dystrophy 92%
- Mechanosensitive Ion Channel Piezo1 Regulates Myocyte Fusion during Skeletal Myogenesis 92%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.